Track GHRP‑2 in Peptimes™
GHRP-2 (pralmorelin) is a synthetic peptide of six amino acids: D-Ala-D-(2-naphthyl)Ala-Ala-Trp-D-Phe-Lys-NH2. FDA's substance registry also lists it as KP-102. (Source: FDA's substance registry (GSRS).)
Is GHRP-2 FDA-approved?
No. GHRP-2 isn't FDA-approved: Drugs@FDA lists no application with it, and FDA puts it on its Category 2 list of bulk substances for compounding that may present significant safety risks.
GHRP-2
Also: pralmorelin, Growth Hormone-Releasing Peptide-2, KP-102, GPA-748
- Status label in the Peptimes Library
- Compounding Restricted
- Routes in Peptimes
- SubcutaneousOther
- Updated
- 1 Nov 2026
US regulatory status
FDA status
Not FDA-Approved. Drugs@FDA lists no application with GHRP-2 (pralmorelin) as an active ingredient.
Source: Drugs@FDA, checked 1 Nov 2026
FDA status
On FDA's Category 2 list: FDA lists growth hormone releasing peptide-2 (GHRP-2), for injectable and nasal routes, among bulk drug substances for compounding that may present significant safety risks, under its interim policy for outsourcing facilities (503B), added 29 Sep 2023.
Source: FDA, checked 1 Nov 2026
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- In humans
A method study for anti-doping laboratories: after GHRP-2 was given to 10 male volunteers, unchanged GHRP-2 and a breakdown product specific to it were found in the urine of all 10.
Source: PMID 20552695, checked 1 Nov 2026
How to track it in Peptimes
Add GHRP-2 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Compounding Restricted”, the app’s label for compounds on FDA’s Category 2 list. Category 2 is FDA’s list of bulk drug substances for compounding that may present significant safety risks; it is not an approval.
- Routes: subcutaneous or Other. Choose the one that matches each dose.
- Logging: the amount you took, the route and how you feel.
- Injection sites: subcutaneous doses record the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next. Doses logged as Other skip this step.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell GHRP-2 or any other compound.
More sources
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks, checked 1 Nov 2026: GHRP-2 (injectable and nasal routes), 503B, added 29 Sep 2023.
- FDA, Global Substance Registration System, Pralmorelin, checked 1 Nov 2026: its sequence and the names GHRP-2, growth hormone-releasing peptide 2 and KP-102.
- Japan, PMDA, GHRP Kaken 100 for injection (pralmorelin hydrochloride), checked 1 Nov 2026: a prescription medicine in Japan whose one labelled use is diagnosing growth hormone deficiency. That approval belongs to that product in Japan only.